Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

The Food and Drug Administration said it will be taking steps to speed up the approval process for developing generic biological drugs, an effort aimed at increasing cheaper competition among ...

A major American medical device manufacturer is investing $110 million to expand production in Nebraska as part of an effort ...

Biologics remain viable options with varying persistence over 1 year in patients with inflammatory bowel disease.

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers. The Food and Drug ...

Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...

DUBLIN--(BUSINESS WIRE)--The "Biological Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Biological Drugs was estimated at ...

Lonza officials say they have expanded the company’s service offering for orally delivered biologic therapies to support the unique development and manufacturing needs of smart capsule companies. Oral ...

With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be no exception to this rule, and with its arrival we ...

Health Secretary Robert F. Kennedy Jr. says he wants to slash the time and cost of approving generic versions of hugely expensive biologic drugs that are driving accelerating health care costs.

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...